A teenager who was under psychiatric “care” was found dead with two antipsychotic drugs in his system. The consulting psychiatrist says he is “puzzled” about his death and that they have “no explanation at all.” Really. Perhaps the good doctor should brush up on the international drug regulatory warnings for the drugs they are prescribing. CCHR’s psychiatric drug database contains 24 international drug regulatory warnings on Antipsychotic drugs, and 49 international studies citing side effects including diabetes, obesity, blood clots, heart problems, cardiac events, cancer, tumors, death/sudden death.
The award came late Thursday evening in a case involving the drug Risperdal, a popular antipsychotic administered for the treatment of schizophrenia and bipolar disorder manufactured by Janssen, a division of Ortho-McNeil-Janssen Pharmaceuticals Inc., which is part of Johnson & Johnson. The jury, which has been hearing the case for almost two months, found the firm misled Louisiana doctors about the possible side effects of the drug.
Johnson & Johnson lost a $257.7 million jury verdict in Louisiana for making misleading claims about the safety of the company’s Risperdal antipsychotic drug.
J&J officials defrauded the state’s Medicaid system by wrongfully touting Risperdal as superior to competing antipsychotic drugs and minimizing its links to diabetes, said jurors in state court in Opelousas, Louisiana.
FOR decades, antipsychotic drugs were a niche product. Today, they’re the top-selling class of pharmaceuticals in America, generating annual revenue of about $14.6 billion and surpassing sales of even blockbusters like heart-protective statins. Lawyers suing AstraZeneca say documents they have unearthed show that the company tried to hide the risks of diabetes and weight gain associated with the new drugs. Positive studies were hyped, the documents show; negative ones were filed away. According to company e-mails unsealed in civil lawsuits, AstraZeneca “buried” — a manager’s term — a 1997 study showing that users of Seroquel, then a new antipsychotic, gained 11 pounds a year, while the company publicized a study that asserted they lost weight. Company e-mail messages also refer to doing a “great smoke-and-mirrors job” on an unfavorable study.
Pharmaceutical manufacturer AstraZeneca, based in Wilmington, Del., has agreed to pay $520 million to settle allegations that it had illegally marketed its antipsychotic drug Seroquel, according to an AZ Central news report.